Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Distribution Agreement

21 Aug 2006 07:01

Marchpole Holdings PLC21 August 2006 Marchpole Holdings plc ("Marchpole") Major distribution agreement for Emanuel Ungaro brand into UAE Marchpole Holdings plc, the fast growing fashion brand management group, ispleased to announce it has today signed a distribution agreement with Dubaibased BTC Group International, for the Emanuel Ungaro brand to be sold in theUnited Arab Emirates. The contract is initially for 5 years, beginning with the 2007 Spring/Summercollection, with an opportunity to extend the agreement. Under the terms of thecontract, BTC will open between three and five exclusive stores within the fiveyear term. The contract is safeguarded with minimum guarantees. BTC is one of the leading wholesalers and retailers for prestigious high fashionbrands in the UAE. Founded in 1998 in Dubai, the Company offers exclusivity fora number of world wide fashion labels including Karl Lagerfeld. Following Marchpole's acquisition in March 2006 of Moda America, the US licenseefor Emanuel Ungaro, which has brought further growth opportunities in the USA,the Company owns the worldwide licence for Emanuel Ungaro. The Emanuel Ungarobrand is already established in Europe and Asia and today's distributionagreement opens up opportunities to benefit from the lucrative Gulf marketplace. Marchpole's Executive Deputy Chairman, Michael Morris, commented: "This agreement is a major breakthrough into the fast growing Gulf marketplaceand one which confirms the significant growth potential of the Ungaro brand. Itis yet further progress towards our strategy to become a global fashion brandmanagement group." - ends - For further information, please contact : Emma KentBell Pottinger Corporate & Financial 020 7861 3232 John Harrison, Finance DirectorMarchpole 020 7908 7777 Note to Editors : • Marchpole Holdings plc ("Marchpole") is an international brand management group that designs, produces and sells clothing and accessories for eight globally recognised fashion labels. It operates in all of the world's main markets - UK, mainland Europe, Asia and the USA • Its respected brands include YSL, Boateng, Emmanuel Ungaro, Ungaro, Jean-Charles de Castelbajac ("JCC"), Jean-Charles de Castelbajac / Rossignol, Jean-Charles de Castelbajac/Okaidi and Homebody • Marchpole is renowned for its integrated approach to brand management, taking a brand from concept to design studio to the customer interface. It is not a clothing manufacturer • The Group has grown considerably in the past 3 years, from a licensee with one core licence (YSL menswear) - to today's international business that manages its brands across a multitude of clothing lines and accessories • Marchpole's recent acquisition (March 2006) of Moda America - the US licensee for leading designer Emanuel Ungaro - brings further growth opportunities in the UK and America and strengthens the company's relationship with Ungaro • The acquisition also allows the company to launch the Ungaro brand, already established by Marchpole in Europe and Asia, into the US, Canada and South America. The acquisition also allows the company to re-launch JCC into America with effect from autumn/winter 2006 • Marchpole will launch the diffusion Ungaro Homme collection in the UK from Spring/Summer 2007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.